Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$1.99 USD
-0.14 (-6.57%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $1.99 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth F Momentum C VGM
Esperion Therapeutics (ESPR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$7.70 | $16.00 | $2.90 | 261.50% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Esperion Therapeutics comes to $7.70. The forecasts range from a low of $2.90 to a high of $16.00. The average price target represents an increase of 261.5% from the last closing price of $2.13.
Analyst Price Targets (7 )
Broker Rating
Esperion Therapeutics currently has an average brokerage recommendation (ABR) of 1.88 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.88 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, four are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 50% and 12.5% of all recommendations. A month ago, Strong Buy made up 50%, while Buy represented 12.5%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.88 | 1.88 | 1.88 | 1.88 | 1.88 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/25/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
3/25/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
3/25/2024 | Northland Capital Markets | Carl Byrnes | Hold | Hold |
2/2/2024 | JMP Securities | Roy Buchanan | Strong Buy | Strong Buy |
1/2/2024 | BTIG | Thomas Shrader | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.88 |
ABR (Last week) | 1.88 |
# of Recs in ABR | 8 |
Average Target Price | $7.70 |
LT Growth Rate | 35.90% |
Industry | Medical - Drugs |
Industry Rank by ABR | 93 of 252 |
Current Quarter EPS Est: | -0.17 |